PT-141 can cost less than people expect. The FDA-approved brand, Vyleesi, is $99 for a four-dose box if your insurance doesn’t cover it, and most commercially insured patients pay $0, as of October 2026. Compounded PT-141 from telehealth sellers runs about $150 to $250 a month, cash only, for off-label use.
Almost everyone who searches “PT-141 cost” is pricing the wrong thing, or rather, they don’t realize there are two things. Bremelanotide — PT-141’s actual drug name — exists as a genuine FDA-approved product, the autoinjector Vyleesi, and it also exists as the compounded nasal spray and injection vial sold all over telehealth and the research-chemical market. Those two products share a molecule and share almost nothing else about how they’re priced. The approved brand is a specialty drug accessed for one narrow medical use; the compounded version is a cash-pay product sold off-label to a much wider audience. This page is about why they cost worlds apart, and what each transaction is really buying. For what the molecule does and what the trials actually show, start with our PT-141 (bremelanotide) evidence review — we won’t re-derive that here.
$99 / 4 doses
Brand Vyleesi without insurance coverage ($0 for most commercially insured)
Vyleesi manufacturer site, October 2026
~$150–$250/mo
Compounded PT-141 off-label — cash-pay, no insurance route
sellers’ public pricing, October 2026
Unknown
Actual content of gray-market “research” PT-141
How much does Vyleesi cost?
Vyleesi is the rare peptide on this beat with a real label. It’s a single-use, on-demand subcutaneous autoinjector, approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — an approval earned by two randomized, placebo-controlled phase-3 trials.[1] That regulatory status sets how it is sold: by prescription, filled through the manufacturer’s chosen digital pharmacy (BlinkRx), which applies the copay and savings programs before you pay.
The price the manufacturer publishes is lower than its “specialty drug” reputation suggests. As of October 2026, the Vyleesi site says most commercially insured patients pay $0 for a four-dose box, and that if you don’t have insurance coverage for Vyleesi, a four-dose box is $99. Patients on government insurance such as Medicaid or TRICARE are not eligible for that assistance, and the program can change at any time, so confirm the figure when you fill.[4] Vyleesi is taken on demand before sexual activity rather than daily, so a box is priced per four doses, not per month. What the program does not change is the label: Vyleesi is approved only for HSDD in premenopausal women. The moment you step outside that use — a man, a general “libido” goal, off-label intent — you are relying on a prescriber’s off-label judgment, and insurance coverage for that use is unlikely.
How much does compounded PT-141 cost?
Strip away the brand and what’s left is the product nearly all the “buy PT-141” traffic is after: compounded bremelanotide, dispensed through telehealth clinics and compounding pharmacies, and sold off-label for men and for general libido well beyond the approved indication. Here pricing is cash-pay and structured like the rest of the peptide telehealth market — you pay for the medication, a clinician review, and shipping, with no insurance in the picture. Published prices in October 2026 run about $150 to $250 a month: Blis MD lists PT-141 from $149 a month, PlexusDx at $189, iThriveMD from $199 and Believe Health from $249. That is not automatically cheaper than the brand’s $99 cash box, so compare the two on the same basis (doses, not months) before assuming the compounded route saves money. The trade-off you’re accepting is off-label, less-supervised use of a product outside the approval that makes Vyleesi reasonable.
How that cash price lands depends heavily on route. The studied, label form is a subcutaneous injection, and compounded injectable vials mirror that — you get a vial of known concentration and dose it per protocol. The cheaper-looking option is the nasal spray, which dodges needles and often carries a lower headline price, but that discount comes with a real catch: intranasal absorption of a peptide is far less predictable than a measured injection, so a lower price per bottle doesn’t cleanly translate to a lower price per effective dose. (It’s worth remembering that an intranasal bremelanotide formulation was actually halted in development over blood-pressure increases — route is not a cosmetic choice.) When you compare nasal-spray and injection prices, you’re not comparing like for like.
Swipe to see all columns
| Product & route | What you typically pay | What the price reflects |
|---|---|---|
| Vyleesi autoinjector (brand, SC injection) | $0 for most commercially insured; $99 per 4-dose box without coverage | Approved, manufactured drug for one narrow indication |
| Compounded PT-141 injection (off-label, SC) | ~$150–$250/month cash via telehealth | Convenience + compounding, no insurance pathway |
| Compounded PT-141 nasal spray (off-label) | Often lowest headline cash price | Cheaper per bottle, but uncertain dose actually absorbed |
| Gray-market “research” PT-141 | Appears cheapest per vial | Unregulated powder of unverified content |
The gray market: a cheap sticker on an unpriced risk
Below even the compounded telehealth tier sits the research-chemical market — PT-141 sold as a powder “for research use only, not for human consumption.” The per-vial price is the whole pitch: it can undercut the telehealth route dramatically. But that disclaimer is doing real work. These vials sit outside the prescription and compounding-pharmacy system, with no one verifying identity, dose, or purity. The closest hard data on what that gamble looks like comes from the adjacent, better-studied gray market for GLP-1 drugs: a 2024 market-surveillance study that actually purchased and lab-tested semaglutide sold online without a prescription found unregistered sellers, orders that never arrived, and analyzed content that diverged from the label, with impurities and dose mismatches.[2] PT-141 bought the same way carries the same structural hazard — you aren’t getting a cheaper version of a known product, you’re getting an unknown one. A low price attached to an unquantified risk isn’t cheap; it’s just unpriced. (To be clear: that’s a cost-versus-risk observation, not a route we recommend — see where to get peptides safely.)
So what does PT-141 actually cost?
The honest answer is that there is no single PT-141 price — there’s a brand price and a compounded price, and they answer different questions. If you are a premenopausal woman with diagnosed HSDD, the relevant cost is Vyleesi: $0 for most commercially insured patients and $99 per four-dose box without coverage, through the manufacturer’s pharmacy program. If you’re among the much larger group buying PT-141 off-label, you’re in the cash-pay compounded market at about $150–$250 a month — with the catch that you’re paying outside the evidence and outside the approval, and the nasal-spray “discount” partly reflects less-certain dosing rather than a true saving. The gray-market vial is cheapest on the sticker and most expensive on risk.
The smart move is the same one we apply to every peptide: anchor what you pay to what’s actually supported. PT-141 is unusual in having real, approved evidence — but only for one indication. Map any spend against that with our peptide evidence matrix, see how PT-141’s pricing logic fits the broader market in our peptide therapy cost breakdown, and if you decide to proceed, compare legitimate telehealth options on care model and price in our peptide therapy provider comparison.
